{
    "clinical_study": {
        "@rank": "152897", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "description": "TNM stage II-IV breast cancer patients with highly trastuzumab-sensitive tumours."
            }, 
            {
                "arm_group_label": "Cohort 2(Control Group)", 
                "description": "TNM stage II-IV breast cancer patients with trastuzumab-refractory disease."
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      The primary aim of the study is:\n\n      1.To identify and validate a panel of molecular and cytogenetic biomarkers able to predict\n      Durable Complete Response (DCR) after chemotherapy and trastuzumab in patients with\n      HER2-positive locally advanced or metastatic breast cancer.\n\n      Secondary Objective:\n\n      The secondary aims of the study are:\n\n        1. To perform a comprehensive exploration of the molecular and cytogenetic characteristics\n           of DCR patients to identify any possible correlation between the tumour's biological\n           and cytogenetic characteristics and the degree of clinical response to trastuzumab;\n\n        2. To produce data in preparation for further translational studies on HER2-positive\n           breast cancer."
        }, 
        "brief_title": "CharactHer. ICORG 12-09, V3", 
        "condition": [
            "HER2-positive Breast Cancer", 
            "TNM Stage II-IV Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Type of Study: Translational\n\n      This is a pilot retrospective laboratory-based cohort study.\n\n      Eligible patients will be identified at each one of the participating institutions by a\n      systematic cross-matching of the datasets of Medical Oncology, Pathology and Pharmacy\n      Departments.\n\n      Patient Population:\n\n      Cohort 1: TNM stage II-IV breast cancer patients with highly trastuzumab-sensitive tumours.\n\n      Cohort 2: (Control group) TNM stage II-IV breast cancer patients with trastuzumab-refractory\n      disease."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria for Cohort 1:\n\n          1. Histologically proven AJCC TNM stage II-IV invasive breast cancer\n\n          2. HER2-positivity defined as score 3+ on IHC and/or with HER2/neu amplification on FISH\n             test (HER2/CEP17 ratio >2.0 on PathVysion test)\n\n          3. Evidence of complete response (CR) according to RECIST 1.1 criteria lasting for at\n             least 36 months (for stage IV patients only) following a first-line chemotherapy and\n             trastuzumab\n\n          4. Pathological Complete Response (pCR) following a neo-adjuvant chemotherapy (CT) and\n             trastuzumab (for stage II-III patients only). pCR is defined as no evidence of\n             residual invasive carcinoma in the breast (ductal carcinoma in situ (DCIS) is\n             allowed) AND in all the examined lymph nodes (micro-metastases and isolated tumour\n             cells are not allowed).\n\n          5. At least one FFPE archived tissue sample from the primary tumour and/or a metastatic\n             site(s) available for laboratory analyses\n\n          6. Adequate follow up information\n\n        Inclusion criteria for Cohort 2:\n\n          1. Histologically proven AJCC TNM stage II-IV invasive breast cancer\n\n          2. HER2-positivity defined as score 3+ on IHC and/or with HER2/neu amplification on FISH\n             test (HER2/CEP17 ratio>2.0 on PathVysion test)\n\n          3. Progression of disease according to RECIST 1.1 while receiving trastuzumab (in\n             association with chemotherapy or as single agent as maintenance therapy) or within 6\n             months from last dose of trastuzumab (for stage IV patients only)\n\n          4. Residual invasive tumour in the breast larger than 2cm and /or at least one micro- or\n             macro-metastasis in the axillary lymph nodes following pre-operative\n             trastuzumab-containing chemotherapy (for stage II-III patients only)\n\n          5. At least one FFPE archived tissue sample from the primary tumour and/or a metastatic\n             site(s) available for laboratory analyses\n\n          6. Adequate follow up information\n\n        Exclusion Criteria:\n\n        1. Any deviation from the above mentioned Inclusion criteria"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Study population will consist of two separate cohorts of patients with HER2-positive\n        breast cancer that will be analysed based on their responsiveness to\n        trastuzumab-containing chemotherapy. Cohort 1 will include patients with TNM stage II-IV\n        breast cancer with highly trastuzumab-sensitive tumours. Results of laboratory analyses\n        from Cohort 1 will be matched with those from Cohort 2 (Control group) that includes\n        patients at the same TNM clinical stages but with trastuzumab-refractory disease."
            }
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01722890", 
            "org_study_id": "ICORG 12-09"
        }, 
        "intervention_browse": {
            "mesh_term": "Trastuzumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HER2-positive breast cancer", 
            "durable complete response", 
            "cytogenetic characteristics", 
            "molecular characteristics", 
            "trastuzumab"
        ], 
        "lastchanged_date": "January 22, 2014", 
        "location": {
            "contact": {
                "last_name": "Contact Person", 
                "phone": "+353 1 221 4000"
            }, 
            "facility": {
                "address": {
                    "city": "Dublin", 
                    "country": "Ireland"
                }, 
                "name": "St. Vincents University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Ireland"
        }, 
        "number_of_groups": "2", 
        "official_title": "CharactHer: A Study of the Molecular and Cytogenetic Characteristics of HER2-positive Breast Cancers to Predict Durable Complete Response After Chemotherapy and Trastuzumab", 
        "overall_official": {
            "affiliation": "St. Vincent's University Hospital", 
            "last_name": "Giuseppe Gullo, Medicine and Surgery", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Ireland: Health Information and Quality Authority"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Panel of molecular and cytogenetic biomarkers able to predict Durable Complete Response (DCR) after chemotherapy and trastuzumab in patients with HER2-positive locally advanced or metastatic breast cancer.", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01722890"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "ICORG- All Ireland Cooperative Oncology Research Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ICORG- All Ireland Cooperative Oncology Research Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}